We are excited to announce that Cmed has today joined the AIXIAL Group and ALTEN Group.

ALTEN is a world leader in Engineering and Technology consulting with 37,000 engineers and scientists located in more than 30 countries throughout the world. It serves customers in a range of industries and has a depth and breadth of experience and expertise across life sciences, software development and artificial intelligence.

AIXIAL Group, an ALTEN company, is a CRO renowned for its flexible and functional resourcing. Through this acquisition, the AIXIAL Group continues to build its global presence with over 1,000 employees. Cmed’s experience, expertise and technology approach perfectly align with the AIXIAL Group’s vision to provide expert services to clients and transform the clinical trials landscape for the benefit of patients.

Cmed Technology is now able to offer an even greater breadth and capability to improve client trial operations through the substantial expertise, capabilities and scale of ALTEN and AIXIAL.

A copy of the recent press releases from ALTEN, Cmed and Aixial are available at this link for your information.

Learn how encapsia can help you!

To book a no-obligation meeting or demonstration please get in touch by using the contact form below:

Contact us

Latest articles

Minimizing Disruption Through Hybrid Clinical Trial Adoption

There have been significant disruptions in the healthcare industry in recent years, particularly in the conduct of clinical trials. The traditional, centralized model of clinical trial design has faced significant challenges in terms of patient recruitment, retention, and overall operational…

Read article

Employee Spotlight: Women in Tech

Q&A with encapsia’s Executive Director of Business Development Temitope Keyes   Superior innovation and performance are achieved with diverse teams that bring new perspectives and skill sets. In acknowledgment of International Women’s Day, we’re shining the spotlight on women in…

Read article

Delayed Clinical Data and Its Impact

The increasing complexity of modern trials demands more intensive data capture. Innovative study designs seek to minimize patient exposure to potential risks, improve convenience and shorten therapy time-to-market —requiring collecting and assimilating more data points than ever before. Data now…

Read article